The supporting action
Small blood vessels carry the GHK-Cu Script
Collagen gets the leading role in skin claims. The blood-vessel findings in a GHK-Cu wound experiment gave me a different scene to follow.¹

Wound angiogenesis in mice
The liposomal GHK-Cu wound experiment has a supporting cast worth watching. The 2017 study reported faster scald-wound healing in mice, with healing by 14 days. Its related work with human blood-vessel-lining cells in culture found proliferation increased by 33.1% versus controls, alongside higher expression of the blood-vessel growth signals VEGF and FGF-2.
Blood vessels supply the tissue being rebuilt. I expected collagen-making cells to carry this story; the endothelial cells, which line vessels, gave me a different point of entry. The repair experiment puts growing cells and a growing blood supply in the same scene. The proposed vessel-growth mechanism addresses how the wound closes, beyond a bare count of days.
The formulation matters here: GHK-Cu was enclosed in liposomes, tiny lipid carriers. The living wound result came from mice, while the human cells were in culture. I want those separate settings visible even as the paper connects them. This is a reason to investigate how repair is coordinated, with a human wound-treatment benefit still to be established.

Satisfaction after laser resurfacing
The scene changes with a randomized trial of 13 patients after CO2 laser resurfacing: satisfaction was significantly higher with the GHK-Cu skin-care regimen. Objective redness and wrinkle improvement showed no statistically significant difference between the groups. The paper appeared in 2006.
That uneven ending appeals to me. A person's pleasure in an outcome matters, and the physical measurements matter too; the trial leaves them sitting beside each other. With so few participants, the absence of a significant difference also leaves considerable uncertainty. Declaring the cream a triumph would flatten the result. So would declaring it useless.
The temptation is to write a tidier ending: repaired skin, a satisfied person, a compound that did what was expected. This experiment supplied only some of that. To me, that unfinished quality deserves more attention than an impressive list of molecular effects.

GHK-Cu in skin care
The more flattering story comes from the 71-woman facial-cream study summarized in the skin-regeneration review. Over 12 weeks, women with photoaged skin had reported improvements in firmness, clarity, fine lines and wrinkle depth, with increased skin density and thickness. That is a substantial reason to take copper-peptide skin care seriously.
The publication trail makes me more cautious about the confidence attached to those findings. The familiar trial reaches this site through a review; the research record identifies a conference presentation rather than a readily available primary journal report. A full trial report would let me judge the comparison and measurements, rather than rely on a favourable summary.
The post-laser trial and the facial-cream findings concern different circumstances. Their differences are worth preserving. The benefits essay follows that tension into the personal reports surrounding these ingredients.
A naturally occurring copper peptide
GHK-Cu joins copper to glycine, histidine and lysine, a chain of three amino acids. Copper Tripeptide-1 is its cosmetic ingredient name. The free GHK peptide occurs in plasma, saliva and urine; its reported plasma level falls with age.
That history helps explain the appeal of a restoration story. Something present in younger bodies becomes less abundant; giving it back sounds like an obvious next act. The experiments on collagen-making cells persuade me more than that leap. An age association leaves the cause of slower repair unresolved, and a replacement benefit still needs to be demonstrated.
The research pages follow the more unruly biology: cells making collagen, cells contracting collagen gels, and wound experiments in which the preparation changes along with the peptide. GHK-Cu copper peptide forms deserve separate attention, because GHK and GHK-Cu can arrive in the same conversation while naming different material.
Treatment status
GHK-Cu isn't FDA-approved for treating an illness. Human skin-cream findings cover a much narrower question than systemic treatment, for which completed Phase 2 or Phase 3 human trials are absent. The amounts used in studies provide experimental context; they do not establish a personal treatment plan.